Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 17/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16794699 | 0.89 | TYK2 (0.41) | TYK2PDE4D | |
| SCHEMBL16794711 | 0.87 | TYK2 (0.39) | TYK2 | |
| SCHEMBL20049687 | 0.84 | TYK2 (0.43) | TYK2PDE4D | |
| SCHEMBL20049684 | 0.83 | TYK2 (0.43) | TYK2PDE4DBRD4CNR2CNR1 | |
| SCHEMBL20049473 | 0.83 | TYK2 (0.43) | TYK2PDE4DBRD4CNR2CNR1 | |
| SCHEMBL20049469 | 0.82 | TYK2 (0.46) | TYK2PDE4D | |
| SCHEMBL20049765 | 0.82 | TYK2 (0.46) | TYK2PDE4D | |
| SCHEMBL20049749 | 0.82 | TYK2 (0.45) | TYK2PDE4D | |
| SCHEMBL20049750 | 0.82 | TYK2 (0.45) | TYK2PDE4D | |
| SCHEMBL16794653 | 0.82 | CNR2 (0.41) | TYK2PDE4DBRD4CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2015089143-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | TYK2, IFNAR1, JAK3 | TYK2 1/4885PDE4D 1717/4885BRD4 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.